Besides the current investigation for AML as mentioned in Section 3.1., anti-CD70 mAb, has also been investigated in heavily pretreated patients with CD70-expressing advanced cutaneous T cell lymphoma. This evidence concerns the gene CD70 and primary cutaneous T-cell non-Hodgkin lymphoma.